StockTake: AdAlta eyes $1.3m boost to fuel East to West cellular immunotherapy strategy

AdAlta (ASX:1AD) has announced aims to raise up to $1.3 million in a renounceable rights issue to advance its East to West cellular immunotherapy strategy. 

Eligible shareholders can apply for two new shares for every three held at $0.03 per share. 

Watch the video to learn more.

This video was developed in collaboration with AdAlta, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.